Alzheimer's disease research and treatmentsDementia and Cognitive Impairment ResearchBiological Research and Disease StudiesHealthcare Decision-Making and RestraintsMultiple Sclerosis Research Studies
Publications
48
Citations
725
Est. group size
—
Recurring co-author estimate
Active years
60
Publishing since 1966
Publication cadence
Publications per year over the last 10 years — averaging 0.4/year recently
Recent publications
- Biomarker pattern of ARIA-E participants in phase 3 randomized clinical trials with bapineuzumab
Neurology · 2018
- Long-Term Extensions of Randomized Vaccination Trials of ACC-001 and QS-21 in Mild to Moderate Alzheimer’s Disease
Current Alzheimer Research · 2017
- Bapineuzumab for mild to moderate Alzheimer’s disease in two global, randomized, phase 3 trials
Alzheimer s Research & Therapy · 2016
- Long-term safety and tolerability of bapineuzumab in patients with Alzheimer’s disease in two phase 3 extension studies
Alzheimer s Research & Therapy · 2016
- VANUTIDE CRIDIFICAR (ACC-001) AND QS-21 ADJUVANT IN INDIVIDUALS WITH EARLY ALZHEIMER’S DISEASE: AMYLOID IMAGING POSITRON EMISSION TOMOGRAPHY AND SAFETY RESULTS FROM A PHASE 2 STUDY
The Journal of Prevention of Alzheimer s Disease · 2016
- A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Safety, Pharmacokinetics, and Biomarker Results of Subcutaneous Bapineuzumab in Patients with mild to moderate Alzheimer’s disease
Journal of Alzheimer s Disease · 2016
- P2‐015: Pooled Amyloid Pet Baseline Data from The Bapineuzumab IV Phase III Trials
Alzheimer s & Dementia · 2016
- Additional file 2: of Long-term safety and tolerability of bapineuzumab in patients with Alzheimer’s disease in two phase 3 extension studies
Figshare · 2016
- Additional file 1: of Long-term safety and tolerability of bapineuzumab in patients with Alzheimer’s disease in two phase 3 extension studies
Figshare · 2016
- Additional file 1: of Long-term safety and tolerability of bapineuzumab in patients with Alzheimer’s disease in two phase 3 extension studies
Figshare · 2016
- Additional file 2: of Long-term safety and tolerability of bapineuzumab in patients with Alzheimer’s disease in two phase 3 extension studies
Figshare · 2016
- Additional file 5: of Bapineuzumab for mild to moderate Alzheimer’s disease in two global, randomized, phase 3 trials
Figshare · 2016
- Additional file 1: of Bapineuzumab for mild to moderate Alzheimerâ s disease in two global, randomized, phase 3 trials
Figshare · 2016
- Additional file 1: of Bapineuzumab for mild to moderate Alzheimerâ s disease in two global, randomized, phase 3 trials
Figshare · 2016
- Additional file 2: of Bapineuzumab for mild to moderate Alzheimerâ s disease in two global, randomized, phase 3 trials
Figshare · 2016
Publishes in
- Figshare×16
- Alzheimer s Research & Therapy×2
- Genetics in Medicine Open×2
- Current Alzheimer Research×1
- Neurology×1
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 9, 2026.
Claim or correct this profile